Results 11 to 20 of about 2,540 (169)

Inclisiran in a real-world single-center registry of patients with very high atherosclerotic cardiovascular risk [PDF]

Atherosclerosis Plus
Background: A mean relative 50 % reduction of LDL cholesterol (LDLc) levels was observed in randomized studies in patients treated with inclisiran, a small-interfering-RNA therapeutic agent that reduces hepatic synthesis of PCSK9.
Antonio Centola, Michelangelo Carbonara, Serena De Nuzzo, Andrea Cuculo, Antonio Ruggiero, Giulio Campanale, Massimo Iacoviello, Paola Gargiulo, Pasquale Perrone Filardi, Natale Daniele Brunetti   +9 more
doaj   +2 more sources

Inclisiran [PDF]

pharma-kritik, 2021
Inclisiran: Inclisiran (Leqvio® ) besteht aus einer kleinen Ribonukleinsäure. Mit Inclisiran-Injektionen alle 6 Monate können die LDL-Cholesterinwerte um rund 50% gesenkt werden, weshalb es bei Personen verwendet werden kann, bei denen Statine nicht genügen oder nicht vertragen werden.
Vijay Nambi, Ali Agha
  +4 more sources

Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease

Vascular Health and Risk Management, 2023
Michael S Albosta,1 Jelani K Grant,2 Pam Taub,3 Roger S Blumenthal,2 Seth S Martin,2 Erin D Michos2 1Internal Medicine Department, University of Miami Miller School of Medicine/ Jackson Memorial Hospital, Miami, FL, USA; 2Ciccarone Center for the ...
Jelani K Grant, Pam R Taub
exaly   +2 more sources

Current usage of inclisiran for cardiovascular diseases: overview of current clinical trials

Frontiers in Pharmacology
BackgroundCardiovascular diseases are predominant health conditions across the world due to their rising prevalence and association with several disorders.
Maan H. Harbi
exaly   +3 more sources

ONE YEAR EXPERIENCE WITH INCLISIRAN IN AN ACADEMIC LIPID CLINIC:

American Journal of Preventive Cardiology, 2023
Therapeutic Area: Pharmacologic Therapy Background: Real-world data examining inclisiran use in US clinical practice are limited. We report a one-year experience with inclisiran in an academic lipid clinic. Methods: Retrospective chart review of patients
Tommy T. Chiou, BA, Kimberly Tomasi, RN, BSN, Pam R. Taub, MD, Michael J. Wilkinson, MD   +3 more
doaj   +1 more source

Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264.7 macrophages via activating the PPARγ pathway

Autoimmunity, 2022
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a well-known proprotein convertase that influences foam cell formation and modulates atherosclerosis. Inclisiran is a novel chemosynthetic small interfering RNA that inhibits PCSK9 synthesis.
Zhaoping Wang, Xiangyu Chen, Jingxing Liu, Yingcui Wang, Suhua Zhang   +4 more
doaj   +1 more source

The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions

Pharmacology Research & Perspectives, 2023
Inclisiran, a small interfering RNA, selectively inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) synthesis in the liver and has been shown to reduce low‐density lipoprotein cholesterol (LDL‐C) by ≥50% in patients with hypercholesterolemia ...
Dario Lehoux, David Kallend, Peter L. J. Wijngaard, Alan P. Brown, Brad Zerler   +4 more
doaj   +1 more source

Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11

American Journal of Preventive Cardiology, 2023
Patients with cerebrovascular disease (CeVD) have been shown to benefit from lipid-lowering therapies, but guideline-recommended levels of low-density lipoprotein cholesterol (LDL-C) are often not attained with statin treatment alone.
Wolfgang Koenig, Kausik K. Ray, Ulf Landmesser, Lawrence A. Leiter, Gregory G. Schwartz, R. Scott Wright, Lorena Garcia Conde, Jackie Han, Frederick J. Raal   +8 more
doaj   +1 more source

An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study

Clinical and Translational Science, 2022
Inclisiran is a small interfering RNA molecule that has been shown to provide an effective and sustained reduction in low‐density lipoprotein cholesterol levels.
David Kallend, Jay Mason, Patrick F. Smith, Michael J. Koren, Robert Stoekenbroek, YanLing He, Peter Wijngaard   +6 more
doaj   +1 more source

Inclisiran: a new generation of lipid-lowering siRNA therapeutic

Frontiers in Pharmacology, 2023
Atherosclerotic heart disease (AHD) is a major cause of morbidity and mortality worldwide. Lowering low-density lipoprotein cholesterol (LDL-C) levels is a key strategy to prevent and treat AHD.
Yanzhen Zhang, Huaigang Chen, Huaigang Chen, Lang Hong, Hong Wang, Bin Li, Mengyin Zhang, Jiamei Li, Liu Yang, Fan Liu   +9 more
doaj   +1 more source